Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

EP: 1.An Overview of the Landscape Surrounding Melanoma

EP: 2.The Role of Biomarker Testing in Melanoma

EP: 3.The Current Landscape Surrounding Adjuvant Therapy in Melanoma

EP: 4.Combination Immunotherapy Strategies for Melanoma in the Adjuvant Setting

EP: 5.Navigating Challenges in Predicting and Mitigating Adverse Events in Adjuvant Immunotherapy

EP: 6.Exploring Immunotherapy Resistance: Impact on Treatment Decisions in Melanoma

EP: 7.Balancing Quality of Life: Adjuvant Therapy Toxicity in Melanoma Adjuvant Immunotherapy

EP: 8.Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

EP: 9.Immunotherapy-Related Diabetes in Melanoma: A Management Perspective

Now Viewing

EP: 10.Immunotherapy-Induced Adrenal Insufficiency in Melanoma: Surveillance and Management

EP: 11.Case 2: 63-Year-Old Female Patient With Metastatic Melanoma on Dual Immunotherapy Developing Treatment-Related Myocarditis

EP: 12.Approaches to Diagnosing and Managing Myocarditis Related to Immunotherapy

EP: 13.Expert Perspectives on Cardiac Baseline and Surveillance Testing in Immunotherapy Recipients

EP: 14.Corticosteroid Treatment Challenges in Patients with Immunotherapy-Related Toxicities

EP: 15.Forward Outlook and Clinical Insights in Melanoma Treatment

This is a video synopsis/summary of an OncLive Insights^® involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

Khushalani notes increased use of various immunotherapy combinations for metastatic or neoadjuvant melanoma, raising concerns for subtle adrenal insufficiency, which is still common. Shariff highlights the importance of maintaining a high suspicion based on subjective fatigue severity/progression and objective trends in weight, blood pressure, and electrolyte level to determine whether laboratory tests are needed. Recognizing adrenal crisis signs preoperatively also matters.

On endocrinopathies, Shariff stresses that they are chronic, so although patients can safely continue immunotherapy, hormone replacement is likely indefinite. She concludes that pretreatment counseling on quality-of-life impacts can help patients understand long-term toxicities such as endocrine dysfunction vs solely emphasizing acute risks when initially consenting.

Video synopsis is AI generated and reviewed by OncLive^® editorial staff.